Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.

M, Nishio; T, Seto; M, Reck; EB, Garon; CH, Chiu; K, Yoh; F, Imamura; K, Park; JY, Shih; C, Visseren-Grul; B, Frimodt-Moller; A, Zimmermann; G, Homma; S, Enatsu; K, Nakagawa

doi:10.1111/cas.14655

Public

Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.

Shared by NobleBlocks on Oct 14, 2020 • 12:00 AM UTC

Authors:

Nishio M

Seto T

Reck M

Abstract

In the global phase III RELAY study, ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression-free survival (PFS) to placebo plus erlotinib (PL + ERL) in untreated patients with epidermal growth factor receptor (EGFR) mutation-positive metastatic non-small-cell lung cancer (NSCLC) (h...

Subject

East Asia

Epidermal growth factor receptor

non-small-cell lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!